key: cord-0691412-pgw4u02l authors: Rogado, Jacobo; Obispo, Berta; Muñoz-Rivas, Nuria; Lara, Miguel Angel title: Incidence of Thromboembolic Events in Cancer Hospitalized Patients With COVID-19 date: 2021-06-04 journal: Chest DOI: 10.1016/j.chest.2021.01.022 sha: 602acedbb2db48607a5f7a153d30feaad9ac8204 doc_id: 691412 cord_uid: pgw4u02l nan To the Editor: In a recent article published in CHEST (March 2021), Jiménez et al 1 conducted a systematic review about the current evidence on the incidence of venous thromboembolic events (VTE) among hospitalized patients with COVID-19. In this article, 48 observational studies were reviewed, detecting an overall incidence of VTE of 17.0%. This incidence was higher in prospective studies including thrombosis screening (33.1% vs 9.8% in clinical diagnosis) and patients admitted to the ICU compared with those admitted to the ward (27.9% vs 7.1%, respectively). In this review, 24% of the total population included in all studies were cancer patients. However, throughout the article there is no reference to this patient subgroup being the most affected by COVID-19. 2 Further sub-analysis was made that allows us to understand what consequences could have a more prothrombotic state in patients with an already greater risk of developing VTE. Cancer patients have inherently 4 to 7 times the risk of developing VTE. 3 As described by Bakouny et al, 4 there is no clear evidence of increased thrombosis in cancer and COVID-19. However, even though there are no studies to support it, they conclude that VTE diagnoses in these patients are probably being underestimated because of strong evidence of a cancer procoagulant state. 4 Nevertheless, in the only study published with cancer patients diagnosed with COVID-19, the incidence of thrombosis was not increased in oncological patients. Patell et al 5 detected a cumulative incidence of VTE of 18.2% in the non-cancer cohort and 14.2% in the cancer cohort. 5 Survival was significantly shorter in the group with active cancer (P ¼ .038), but, surprisingly, the cumulative incidence of major and fatal bleeding was similar, 20.8% in the non-cancer group and 19.5% in the cancer cohort. 5 Therefore, a great question must be answered: Is there really a procoagulant summation effect between cancer and COVID-19? We hypothesized that when cancer patients develop the COVID-19 cytokine storm that could generate VTE, these patients are already in a critical situation with a high mortality (in our series approximately 40%), probably dying without time enough to develop thrombosis, 2 or they may be underdiagnosed in those critically ill patients with a very bad prognosis, especially in the first weeks of the pandemic. These points might be the reasons for a lower cumulative incidence of VTE in cancer patients. To the Editor: We thank Dr Rogado and colleagues for their thoughtful comments about our systematic review and metaanalysis findings. 1 Importantly, as stated and shown in our meta-analysis, original studies based on retrospective chart review are prone to limitations with respect to outcome identification and ascertainment. In addition, small studies are prone to type I error, or failure to show a difference in patients with and without cancer. Although we value the opportunity to further clarify incidence rates for certain subgroups of patients (eg, cancer patients) beyond our initial report, sufficient information from the original studies was not available to allow such analyses. Results of careful analyses from large registries of patients with COVID-19, ideally with prospective outcome ascertainment, and metaanalyses of individual patient data 2 would be complex and time-consuming but may provide opportunities for in-depth subgroup analyses and may be pursued in the future. To the Editor: Interpretation of pulmonary function tests is important and is addressed in CHEST (October 2020) by Neder et al. 1 However, their description of lung diffusing capacity interpretation is convoluted. A much simpler, intuitive interpretation of diffusing capacity is based on the effect of lung volume on the diffusing capacity of the lung for carbon monoxide (DLCO) and carbon monoxide transfer coefficient (KCO) (DLCO/volume of distribution of the tracer gas during DLCO maneuver-predicted dead space [VA]). DLCO and KCO change with lung volume in a manner expected from having DLCO depend on the surface area for gas exchange with the capillary blood component unchanged. 2 chestjournal.org Normative peak cardiopulmonary exercise test responses in Canadian adults aged $40 years Quantification of cardiorespiratory fitness in healthy nonobese and obese men and women Normative cardiopulmonary exercise test responses at the ventilatory threshold in Canadian adults 40 to 80 years of age Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid Venous thromboembolism and cancer: risks and outcomes COVID-19 and cancer: current challenges and perspectives Incidence of thrombosis and hemorrhage in hospitalizaed cancer patients with COVID-19 Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data